leukemia inhibitory factor Search Results


93
MedChemExpress human leukemia inhibitory factor
Human Leukemia Inhibitory Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Animal-Free+LIF%2C+Human/pm40168696-74-82-86
Average 93 stars, based on 1 article reviews
human leukemia inhibitory factor - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
Kingfisher Biotech feline leukemia inhibitory factor
Feline Leukemia Inhibitory Factor, supplied by Kingfisher Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Feline+Leukemia+Inhibitory+Factor+(LIF)+Recombinant+Protein/pm40254569-60-67-72
Average 94 stars, based on 1 article reviews
feline leukemia inhibitory factor - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
Proteintech rabbit anti lif
Rabbit Anti Lif, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/LIF+Antibody/pmc12749643-267-6-9
Average 93 stars, based on 1 article reviews
rabbit anti lif - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
MedChemExpress lif

Lif, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/LIF%2C+Human/pmc09468384-49-0-2
Average 94 stars, based on 1 article reviews
lif - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Alomone Labs leukemia inhibitory factor

Leukemia Inhibitory Factor, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Recombinant+human+LIF+protein/pmc10931382-88-94-99
Average 94 stars, based on 1 article reviews
leukemia inhibitory factor - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

92
MedChemExpress leukemia inhibitory factor receptor lifr inhibitor
Fig. 4 PTHrP differentially regulates p27 through <t>LIFR</t> in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, <t>50nM</t> or <t>100nM)</t> for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM
Leukemia Inhibitory Factor Receptor Lifr Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/LIFR%2C+Human/pm38409028-192-9-18
Average 92 stars, based on 1 article reviews
leukemia inhibitory factor receptor lifr inhibitor - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

94
Proteintech human leukemia inhibitory factor
Fig. 4 PTHrP differentially regulates p27 through <t>LIFR</t> in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, <t>50nM</t> or <t>100nM)</t> for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM
Human Leukemia Inhibitory Factor, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Animal-free+Recombinant+Human+LIF/med_rxiv__64898__2026__03__03__26347354-276-27-34
Average 94 stars, based on 1 article reviews
human leukemia inhibitory factor - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Kingfisher Biotech clif
Fig. 4 PTHrP differentially regulates p27 through <t>LIFR</t> in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, <t>50nM</t> or <t>100nM)</t> for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM
Clif, supplied by Kingfisher Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Chicken+Leukemia+Inhibitory+Factor+(LIF)+Recombinant+Protein/pm42201174-201-136-137
Average 94 stars, based on 1 article reviews
clif - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

86
Cusabio leukemia inhibitory factor lif
Fig. 4 PTHrP differentially regulates p27 through <t>LIFR</t> in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, <t>50nM</t> or <t>100nM)</t> for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM
Leukemia Inhibitory Factor Lif, supplied by Cusabio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Human+Leukemia+inhibitory+factor%2CLIF+ELISA+kit/pmc05639308-171-19-41
Average 86 stars, based on 1 article reviews
leukemia inhibitory factor lif - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

93
Kingfisher Biotech monkey lif
Fig. 4 PTHrP differentially regulates p27 through <t>LIFR</t> in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, <t>50nM</t> or <t>100nM)</t> for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM
Monkey Lif, supplied by Kingfisher Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Cynomolgus+Monkey+Leukemia+Inhibitory+Factor+(LIF)+Recombinant+Protein/us11390670-752-41-44
Average 93 stars, based on 1 article reviews
monkey lif - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Cusabio rat lif elisa kit
Figure 4. Correlation across assays of 200 selected compounds from HTS. (A) <t>LIF</t> production activation fold in U87-MG cells, AlphaScreen vs. <t>ELISA</t> (r2 = 0.753). (B) LIF production activation fold in AlphaScreen assay format, U87-MG vs. WM-115 cells (r2 = 0.347). Shape by chemical clustering: circles, cluster 3; squares, cluster 5; triangle, other cluster.
Rat Lif Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Rat+leukemia+inhibitory+factor%2CLIF+ELISA+Kit/pm26984928-31-0-6
Average 93 stars, based on 1 article reviews
rat lif elisa kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
OriGene leukemia inhibitory factor
Figure 4. Correlation across assays of 200 selected compounds from HTS. (A) <t>LIF</t> production activation fold in U87-MG cells, AlphaScreen vs. <t>ELISA</t> (r2 = 0.753). (B) LIF production activation fold in AlphaScreen assay format, U87-MG vs. WM-115 cells (r2 = 0.347). Shape by chemical clustering: circles, cluster 3; squares, cluster 5; triangle, other cluster.
Leukemia Inhibitory Factor, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukemia+inhibitory+factor/Leukemia+inhibitory+factor+Mouse+Protein/pmc12804927-300-52-56
Average 93 stars, based on 1 article reviews
leukemia inhibitory factor - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Journal: iScience

Article Title: MCM7 supports the stemness of bladder cancer stem-like cells by enhancing autophagic flux

doi: 10.1016/j.isci.2022.105029

Figure Lengend Snippet:

Article Snippet: LIF , MedChemExpress , Cat. # HY-P73276.

Techniques: Recombinant, MTS Assay, Protein Concentration, Software

Fig. 4 PTHrP differentially regulates p27 through LIFR in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, 50nM or 100nM) for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM

Journal: Breast cancer research : BCR

Article Title: PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.

doi: 10.1186/s13058-024-01791-z

Figure Lengend Snippet: Fig. 4 PTHrP differentially regulates p27 through LIFR in breast cancer cells. (A) Immunofluorescence staining and quantification of LIFR in primary tumors from mice inoculated with MSCV, FLSEC, DNLS, or DNLS + CTERM cells. All panels = 40X and scale bars = 50 μm. (B) Western blot analysis of p27, pERK, ERK, p-p38, p38 and tubulin (loading control) protein levels in MSCV, FLSEC, DNLS, or DNLS + CTERM cells treated with vehicle (DMSO) or LIFR inhibitor (EC359, 50nM or 100nM) for 24 h. Densitometry for western blot analysis of (C) p27, (D) pERK/ERK and (E) p-p38/p38 described in (B). (A) **p < 0.01 vs. DNLS by unpaired t-test. (C) *p < 0.05 vs. DNLS by unpaired t-test or *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons. (D & E) *p < 0.05 vs. MSCV by one-way ANOVA with multiple comparisons or *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle by two-way ANOVA. Graphs represent mean ± SEM

Article Snippet: The following day, cells were treated with EC359, a leukemia inhibitory factor receptor (LIFR) inhibitor (50nM or 100nM; MedChemExpress; Catalog No. HY-1,201,420) or vehicle (0.1% dimethyl sulfoxide, DMSO) for 1, 6, or 24 h in full-serum media.

Techniques: Immunofluorescence, Staining, Western Blot, Control

Fig. 6 Model of PTHrP domain-specific actions in breast cancer progression and bone colonization. In the primary breast site (top left panel, left of ar rows), PTHrP lacking the NLS and C-terminal domain decreases tumor cell proliferation through p27 induction driven by the tumor suppressor leukemia inhibitory factor receptor (LIFR). PTHrP lacking the NLS and C-terminal domain also preferentially induces p38 phosphorylation and signaling to inhibit cell cycling downstream of LIFR activation. In the breast, truncated PTHrP lacking the NLS alone (top left panel, right of arrows) downregulates LIFR expression (denoted by transparent coloring) and prevents induction of p27 expression and activation of p38 signaling (denoted by dashed arrows, dot ted outlines and transparent coloring) to drive cell proliferation and tumor growth. In bone disseminated tumor cells (bottom panel), LIFR expression is downregulated and the induction of p27 by PTHrP lacking the NLS and C-terminal domain persists, but is not sufficient to repress metastatic outgrowth (denoted by dashed inhibitor line), in contrast to the primary tumor. In the bone, tumor cells expressing PTHrP peptides lacking the NLS or NLS and C- terminal domain readily proliferate into metastatic tumors. Image created with Biorender.com

Journal: Breast cancer research : BCR

Article Title: PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.

doi: 10.1186/s13058-024-01791-z

Figure Lengend Snippet: Fig. 6 Model of PTHrP domain-specific actions in breast cancer progression and bone colonization. In the primary breast site (top left panel, left of ar rows), PTHrP lacking the NLS and C-terminal domain decreases tumor cell proliferation through p27 induction driven by the tumor suppressor leukemia inhibitory factor receptor (LIFR). PTHrP lacking the NLS and C-terminal domain also preferentially induces p38 phosphorylation and signaling to inhibit cell cycling downstream of LIFR activation. In the breast, truncated PTHrP lacking the NLS alone (top left panel, right of arrows) downregulates LIFR expression (denoted by transparent coloring) and prevents induction of p27 expression and activation of p38 signaling (denoted by dashed arrows, dot ted outlines and transparent coloring) to drive cell proliferation and tumor growth. In bone disseminated tumor cells (bottom panel), LIFR expression is downregulated and the induction of p27 by PTHrP lacking the NLS and C-terminal domain persists, but is not sufficient to repress metastatic outgrowth (denoted by dashed inhibitor line), in contrast to the primary tumor. In the bone, tumor cells expressing PTHrP peptides lacking the NLS or NLS and C- terminal domain readily proliferate into metastatic tumors. Image created with Biorender.com

Article Snippet: The following day, cells were treated with EC359, a leukemia inhibitory factor receptor (LIFR) inhibitor (50nM or 100nM; MedChemExpress; Catalog No. HY-1,201,420) or vehicle (0.1% dimethyl sulfoxide, DMSO) for 1, 6, or 24 h in full-serum media.

Techniques: Phospho-proteomics, Activation Assay, Expressing

Figure 4. Correlation across assays of 200 selected compounds from HTS. (A) LIF production activation fold in U87-MG cells, AlphaScreen vs. ELISA (r2 = 0.753). (B) LIF production activation fold in AlphaScreen assay format, U87-MG vs. WM-115 cells (r2 = 0.347). Shape by chemical clustering: circles, cluster 3; squares, cluster 5; triangle, other cluster.

Journal: Journal of biomolecular screening

Article Title: Discovery of Enhancers of the Secretion of Leukemia Inhibitory Factor for the Treatment of Multiple Sclerosis.

doi: 10.1177/1087057116638821

Figure Lengend Snippet: Figure 4. Correlation across assays of 200 selected compounds from HTS. (A) LIF production activation fold in U87-MG cells, AlphaScreen vs. ELISA (r2 = 0.753). (B) LIF production activation fold in AlphaScreen assay format, U87-MG vs. WM-115 cells (r2 = 0.347). Shape by chemical clustering: circles, cluster 3; squares, cluster 5; triangle, other cluster.

Article Snippet: Rat LIF ELISA kit was from Cusabio (Wuhan, China).

Techniques: Activation Assay, Amplified Luminescent Proximity Homogenous Assay, Enzyme-linked Immunosorbent Assay